Urinary incontinence is a common problem where leakage of urine occurs involuntarily from the bladder. Urinary incontinence can happen due to various reasons such as age related weakening of pelvic floor muscles, obesity, giving birth to a child, neurological disorders, and more. The global urinary continence treatment drugs market offers a wide range of prescription medications to treat urinary incontinence which provide relief from bladder leakage. Drugs such as anticholinergic, Botox, beta-3 adrenergic agonists and other medications helps in improving bladder control by reducing spasms and strengthening the bladder muscle tone.
The Global Urinary Incontinence Treatment Drugs Market is estimated to be valued at US$ 4.41 Bn in 2023 and is expected to exhibit a CAGR of 3.4% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the urinary incontinence treatment drugs are Astellas Pharma, Pfizer Inc., Teva Pharmaceutical Industries Limited, Novartis AG, Mylan N.V.
Urinary Incontinence Treatment Drugs Market Size include increasing geriatric population prone to develop urinary incontinence due to age related muscle weakening, rising awareness about available treatment options, technological advancements leading to development of novel drug formulations.
Major players are expanding globally driven by increasing healthcare investments in emerging markets of Asia Pacific and Latin America. Moreover, strategic collaborations between regional and international pharmaceutical companies is also expected to boost the market expansion.
Market Drivers
The growing geriatric population is a major driver for the urinary incontinence treatment drugs market. Age related weakening of pelvic floor muscles and bladder support structures increases risk of incontinence. According to WHO, number of people aged 65 years and above is projected to reach 1.5 billion by 2050 from present 703 million in 2019.
Market Restrain
Side effects associated with usage of urinary incontinence drugs such as dry mouth, constipation, blurred vision etc. act as a restraint. Additionally, availability of alternative treatment options like pelvic floor exercises and implant devices poses competition to drug therapies. High costs of branded drugs is another factor limiting widespread adoption.
Segment Analysis
The urinary incontinence treatment drugs market can be segmented based on product type into hormonal and non-hormonal drugs. The hormonal drugs segment currently dominates the market owing to the high effectiveness of these drugs in treating stress urinary incontinence. Within hormonal drugs, the duloxetine drug sub-segment holds the largest market share as duloxetine is the most prescribed drug for stress urinary incontinence treatment.
Global Analysis
North America currently dominates the urinary incontinence treatment drugs market and is expected to continue its dominance over the forecast period. High awareness levels regarding the treatment and management options for urinary incontinence coupled with the availability of advanced healthcare facilities are major factors driving the North American market. The Asia Pacific market is projected to grow at the fastest pace due to the rising geriatric population, improving access to healthcare, and growing priority on women’s health issues in emerging economies of the region.
Get This Report in Japanese Language: 尿失禁治療薬市場
Get This Report in Korean Language: 요실금 치료 약물 시장
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
Comments
0 comment